<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03300401</url>
  </required_header>
  <id_info>
    <org_study_id>3L-17-3</org_study_id>
    <secondary_id>NCI-2017-01422</secondary_id>
    <secondary_id>3L-17-3</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT03300401</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization</brief_title>
  <official_title>The Role of Quantitative Contrast-Enhanced Ultrasound in Yttrium-90 (90Y) Radioembolization of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing
      patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced
      ultrasound may provide detailed imaging of the tumor arteries after the injection of a
      contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit
      in the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Investigate the relationship between hepatocellular carcinoma (HCC) tumor perfusion on
      pre-procedural contrast-enhanced ultrasound (CEUS) time intensity curve (TIC) and
      post-procedural Yttrium-90 (90Y) microsphere distribution after 90Y radioembolization (RE).

      SECONDARY OBJECTIVES:

      I. Study the potential of serial CEUS TIC examinations as a marker of tumor treatment
      response as assessed at 20 - 24 week computed tomography (CT) follow-up.

      OUTLINE:

      Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at
      baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo positron emission
      tomography/computed tomography (PET/CT) after standard of care 90Y radioembolization at
      baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">November 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tumor response to therapy</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Will be assessed by modified Response Evaluation Criteria in Solid Tumors criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perflutren Lipid Microspheres</intervention_name>
    <description>Receive intravenous injection just prior to ultrasound</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>Definity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfur Hexafluoride Lipid Microspheres</intervention_name>
    <description>Receive intravenous injection just prior to ultrasound</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>Lumason</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Contrast-Enhanced Ultrasound Imaging</intervention_name>
    <description>Undergo Contrast-Enhanced Ultrasound Imaging</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>Contrast-Enhanced Ultrasound Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo CT scan</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>Computerized Axial Tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Yttrium-90 (90Y)</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>90Y microsphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for 90Y radioembolization for HCC as part of their standard of care

        Exclusion Criteria:

          -  Patients who have already received tumor treatment (either systemic or loco-regional
             such as previous Y90RE, microwave or radiofrequency [RF] ablation or transarterial
             chemoembolization [TACE])

          -  Pregnant or nursing

          -  Known cardiac shunt

          -  Known pulmonary hypertension

          -  History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason

          -  History of hypersensitivity to iodinated contrast agent

          -  Cannot consent for himself or herself
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harshawn Malhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosy Diaz</last_name>
    <phone>323-442-7469</phone>
    <email>Rosaura.diaz@med.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bushan Desai</last_name>
    <phone>323-442-7469</phone>
    <email>Bhushan.Desai@med.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosy Diaz</last_name>
      <phone>323-442-7469</phone>
      <email>Rosaura.diaz@med.usc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

